Policy to expand Medicaid coverage linked to higher participation in cancer clinical trials

Eric Small, ASCO’s immediate past president, speaks on the toll of toxicity—financial, emotional, physical—in cancer
“Discovery alone is not enough. It’s about what becomes of what we discover. It’s about translation.”

In a poignant keynote punctuated with anecdotes about grief, American Society of Clinical Oncology’s immediate past president Eric Small emphasized that the annual conference is not just about scientific discovery, but about a responsibility to translate discoveries into better outcomes for cancer patients globally.

June 05, 2026

Vol.52 No.22

By Claire Marie Porter

Cancer Policy

Cancer patients could be exempted from Medicaid work requirements if they prove they are “medically frail”

The Centers for Medicare & Medicaid Services has released a guidance for states on how to implement Medicaid work requirements that will go into effect nationwide on Jan. 1, 2027.

Teclistamab improves outcomes in relapsed MM, phase III trial finds

An international phase III study showed that patients with relapsed multiple myeloma treated with teclistamab lived longer and remained in remission significantly longer than patients receiving standard therapies.

June 05, 2026

Vol.52 No.22

Clinical Roundup

Adding immunotherapy to radiation improves disease-free survival in localized prostate cancer, phase III trial finds

Adding the investigational adenoviral-based viral immunotherapy aglatimagene besadenovec (alglatimagene, CAN-2409) to standard radiation therapy improved disease-free survival for patients with intermediate- or high-risk localized prostate cancer, according to the results of a multicenter clinical trial led by researchers at the Johns Hopkins University School of Medicine, Johns Hopkins Kimmel Cancer Center, Department of Radiation Oncology and Molecular Radiation Sciences, and Brady Urological Institute.

June 05, 2026

Vol.52 No.22

Clinical Roundup

Camizestrant combination delayed time to first progression by 55% in patients with advanced HR+ breast cancer with ESR1 tumor mutation

Further positive results from the phase III SERENA-6 trial showed camizestrant plus a cyclin-dependent kinase 4/6 inhibitor—palbociclib, ribociclib or abemaciclib—maintained its progression-free survival benefit with longer follow-up and delivered a statistically significant and clinically meaningful improvement in second progression-free survival, demonstrating sustained benefit beyond initial treatment.

June 05, 2026

Vol.52 No.22

Clinical Roundup

OST-HER2 achieves 2.5-year OS in fully resected pulmonary metastatic osteosarcoma, phase IIb trial finds

OST-HER2 (OST31-164) achieved statistically significant benefit for treated patients in overall survival at the 2.5-year timepoint in the prevention or delay of recurrence in fully resected, pulmonary metastatic osteosarcoma (75% vs. 47%, p = 0.003).

June 05, 2026

Vol.52 No.22

Policy to expand Medicaid coverage linked to higher participation in cancer clinical trials

YOU MAY BE INTERESTED IN

Eric Small, ASCO’s immediate past president, speaks on the toll of toxicity—financial, emotional, physical—in cancer
“Discovery alone is not enough. It’s about what becomes of what we discover. It’s about translation.”

Cancer patients could be exempted from Medicaid work requirements if they prove they are “medically frail”

Teclistamab improves outcomes in relapsed MM, phase III trial finds

Adding immunotherapy to radiation improves disease-free survival in localized prostate cancer, phase III trial finds

Camizestrant combination delayed time to first progression by 55% in patients with advanced HR+ breast cancer with ESR1 tumor mutation

OST-HER2 achieves 2.5-year OS in fully resected pulmonary metastatic osteosarcoma, phase IIb trial finds

Renew today!

Subscriber content

Never miss an issue!

Login

Policy to expand Medicaid coverage linked to higher participation in cancer clinical trials

YOU MAY BE INTERESTED IN

Eric Small, ASCO’s immediate past president, speaks on the toll of toxicity—financial, emotional, physical—in cancer“Discovery alone is not enough. It’s about what becomes of what we discover. It’s about translation.”

Cancer patients could be exempted from Medicaid work requirements if they prove they are “medically frail”

Teclistamab improves outcomes in relapsed MM, phase III trial finds

Adding immunotherapy to radiation improves disease-free survival in localized prostate cancer, phase III trial finds

Camizestrant combination delayed time to first progression by 55% in patients with advanced HR+ breast cancer with ESR1 tumor mutation

OST-HER2 achieves 2.5-year OS in fully resected pulmonary metastatic osteosarcoma, phase IIb trial finds

Never miss an issue!

Login

Eric Small, ASCO’s immediate past president, speaks on the toll of toxicity—financial, emotional, physical—in cancer
“Discovery alone is not enough. It’s about what becomes of what we discover. It’s about translation.”